Publication:
5-Aminosalicylic acid associated chronic tubulointerstitial nephritis in a patient with Crohn's disease

dc.contributor.authorsKoc M., Cetin Ozener I., Bihorac A., Kilicaslan I., Akoglu E.
dc.date.accessioned2022-03-28T14:50:42Z
dc.date.accessioned2026-01-10T16:56:05Z
dc.date.available2022-03-28T14:50:42Z
dc.date.issued2000
dc.description.abstract5-Aminosalicylic acid (5-ASA) is the most commonly used drug for the treatment of inflammatory bowel disease (IBD). 5-aminosalicylic acid induced nephrotoxicity has recently been reported. We report a case of female with Crohn's disease treated with mesalazine for 60 months and sulphasalazine for additional 12 months. The patient presented with loin pain, sterile pyuria and raised serum creatinine. Percutaneous renal biopsy revealed chronic interstitial nephritis and yellow-brown pigment deposition in proximal tubular cells. Steroid treatment was commenced for 4 months and there has been no improvement in renal function. Due to widespread use of mesalazine, and its insidious onset of nephrotoxicity, renal function screening and urinalysis should be routinely performed to detect the toxicity of mesalazine and related drugs.
dc.identifier.issn10191941
dc.identifier.urihttps://hdl.handle.net/11424/255513
dc.language.isoeng
dc.relation.ispartofMarmara Medical Journal
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject5-ASA
dc.subjectChronic interstitial nephritis
dc.subjectMesalazine
dc.subjectSulphasalizine
dc.title5-Aminosalicylic acid associated chronic tubulointerstitial nephritis in a patient with Crohn's disease
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage229
oaire.citation.issue4
oaire.citation.startPage226
oaire.citation.titleMarmara Medical Journal
oaire.citation.volume13

Files